Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Sangamo Biosciences Inc (SGMO)  
$0.52 0.04 (6.83%) as of 4:30 Wed 4/10


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 140,990,000
Market Cap: 73.88(M)
Last Volume: 2,041,307 Avg Vol: 1,748,484
52 Week Range: $0.2971 - $1.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 11,784
Total Buy Value $0 $0 $0 $43,025
Total People Bought 0 0 0 2
Total Buy Transactions 0 0 0 2
Total Shares Sold 0 0 6,000,000 6,500,000
Total Sell Value $0 $0 $3,000,000 $5,657,240
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 3
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 1096
  Page 1 of 44  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER   •       –      –    2024-02-25 4 D $1.13 $3,902 D/D (3,453) 834,578     -
   Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY   •       –      –    2024-02-25 4 D $1.13 $3,902 D/D (3,453) 836,430     -
   Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER   •       –      –    2024-02-25 4 D $1.13 $5,661 D/D (5,010) 846,188     -
   Pooler Amy VP, HEAD OF RESEARCH   •       –      –    2024-02-25 4 D $1.13 $2,779 D/D (2,459) 196,314     -
   Macrae Sandy PRESIDENT, CEO AND DIRECTOR   •       •      –    2024-02-25 4 D $1.13 $27,297 D/D (24,157) 2,552,204     -
   Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER   •       –      –    2024-02-24 4 D $1.13 $6,186 D/D (5,474) 838,031     -
   Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY   •       –      –    2024-02-24 4 D $1.13 $4,948 D/D (4,379) 839,883     -
   Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER   •       –      –    2024-02-24 4 D $1.13 $6,186 D/D (5,474) 851,198     -
   Pooler Amy VP, HEAD OF RESEARCH   •       –      –    2024-02-24 4 D $1.13 $2,496 D/D (2,209) 198,773     -
   Macrae Sandy PRESIDENT, CEO AND DIRECTOR   •       •      –    2024-02-24 4 D $1.13 $18,210 D/D (16,115) 2,576,361     -
   Macrae Sandy PRESIDENT, CEO AND DIRECTOR   •       •      –    2024-01-22 4 A $0.00 $0 D/D 2,000,000 2,592,476     -
   Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER   •       –      –    2024-01-22 4 A $0.00 $0 D/D 712,500 843,505     -
   Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY   •       –      –    2024-01-22 4 A $0.00 $0 D/D 712,500 844,262     -
   Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER   •       –      –    2024-01-22 4 A $0.00 $0 D/D 712,500 856,672     -
   Pooler Amy VP, HEAD OF RESEARCH   •       –      –    2024-01-22 4 A $0.00 $0 D/D 150,000 200,982     -
   Willoughby Scott B. SVP, Gen. Counsel & Secretary   •       –      –    2023-11-25 4 D $0.38 $508 D/D (1,329) 126,762     -
   Fontenot Jason D. SVP, Chief Scientific Officer   •       –      –    2023-11-25 4 D $0.38 $394 D/D (1,030) 136,270     -
   Duraibabu Prathyusha SVP, Chief Financial Officer   •       –      –    2023-11-25 4 D $0.38 $508 D/D (1,329) 131,005     -
   Dubois-Stringfellow Nathalie SVP-Chief Development Officer   •       –      –    2023-11-25 4 D $0.38 $559 D/D (1,462) 139,172     -
   Pooler Amy VP, Head of Research   •       –      –    2023-11-25 4 D $0.38 $187 D/D (490) 50,982     -
   Mcclung David Mark EVP, Chief Operating Officer   •       –      –    2023-11-25 4 D $0.38 $736 D/D (1,925) 212,471     -
   Macrae Sandy President, CEO and Director   •       •      –    2023-11-25 4 D $0.38 $3,978 D/D (10,411) 592,476     -
   Pooler Amy VP, Head of ResearchOfficer   •       –      –    2023-11-20 3 IO $0.00 $0 D/D 0 51,472     -
   Biogen Ma Inc. 10% Owner   –       –       •   2023-09-26 4 S $0.50 $3,000,000 I/I (6,000,000) 17,652,466     -
   Macrae Sandy President, CEO and Director   •       •      –    2023-08-25 4 D $0.77 $8,016 D/D (10,411) 602,887     -
  1096 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 44
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us